Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(04): 151-153
DOI: 10.4103/sajc.sajc_183_16
Original Article : Genitourinary & Gynecological Cancers

Prognostic significance of bone only metastasis compared to visceral metastasis in patients with carcinoma cervix treated with platinum-based chemotherapy

Suresh Babu Mallekavu
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Aditi Harsh Thanky
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Govind Babu Kanakasetty
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Lakshmaiah Kuntegowdanahalli
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Lokanatha Dasappa
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Linu A. Jacob
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
› Author Affiliations Source of Support: Nill.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Context: Carcinoma cervix is a leading cause of cancer in Indian females where 15%–60% of the cases eventually metastasize. Bone only metastasis is rare, and data on its response and survival with systemic therapy as compared to other visceral metastasis are limited. Settings and Design: The study design was a retrospective analysis. Materials and Methods: We retrospectively analyzed our data between May 2013 and April 2015 to identify the cases of bone only metastasis and visceral metastasis and tried to analyze their outcomes with paclitaxel- and carboplatin-based chemotherapy and bisphosphonates (for bone metastasis only). Results: Totally, 12 cases with bone only metastasis (Group 1) and 43 cases with visceral metastasis (Group 2) were identified. Most common sites of bone metastasis were vertebrae (66.67%) and pelvis (25%) while that of visceral metastasis was liver (44.18%) and lung (34.88%). Only 33.33% and 34.88% of cases in Group 1 and Group 2, respectively, could complete all six cycles of chemotherapy. Overall, response rates were 41.67% and 30.32% in Group 1 and Group 2, respectively. Median progression-free survival and overall survival (OS) were 10 months and 14 months, respectively, in Group 1 as compared to 4 months and 9 months, respectively, in Group 2. The difference in survival was statistically significant. Statistical Analysis Used: It was carried out by SPSS software version 20. Conclusion: Bone only metastasis is a rare and distinct entity with favorable outcomes as compared to visceral metastasis. However, disease remains aggressive and poor OS emphasizing the need of further research.

Key words

Bone metastasis - cervical carcinoma - visceral metastasis


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Cervical Cancer. International Agency for Research on Cancer, World Health Organization; 2015. Available from: http://www.globocan.iarc fr/old/FactSheets/cancers/cervix-new.asp. [Last accessed on 2016 Apr 03].
  • 2 Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1992;24:197-204.
  • 3 ICO Information Centre on HPV and Cancer. Human Papillomavirus and Related Diseases in India (Summary Report 2014-08-22); 2014.
  • 4 Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feurer EJ, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007.
  • 5 Blythe JG, Cohen MH, Buchsbaum HJ, Latourette HB. Bony metastases from carcinoma of cervix. Occurrence, diagnosis, and treatment. Cancer 1975;36:475-84.
  • 6 Fulcher AS, O'Sullivan SG, Segreti EM, Kavanagh BD. Recurrent cervical carcinoma: Typical and atypical manifestations. Radiographics 1999;19:S103-16.
  • 7 Philipp E. Rontgenologic Dantellung of Tissue Disorders in the Uterus Cancer and its Course. Zentralbl. Gynaekol. 1932; 56:45-58.
  • 8 Albers-Schonberg H. Contributions to the Statistics of the Carcinoma Uteri. Jahrbwh der Hamburgische Staatskrankenunst 1893-1894.
  • 9 Drescher H. To the Clinic of Adenocarcinoma of the Cervix Uteri. Ceburtshilfe Frauenheilkd 1949;9:31-7.
  • 10 Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
  • 11 Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059-67.
  • 12 Matsuyama T, Tsukamoto N, Imachi M, Nakano H. Bone metastasis from cervix cancer. Gynecol Oncol 1989;32:72-5.
  • 13 Tsubamoto H, Inoue K, Ukita Y, Ito Y, Kanazawa R. Long-term remission after multiple bone metastases following cervical cancer: A case report. Gynecol Oncol Case Rep 2013;5:22-4.